On Monday, Corcept Therapeutics Inc (NASDAQ: CORT) opened lower -6.54% from the last session, before settling in for the closing price of $72.27. Price fluctuations for CORT have ranged from $29.42 to $117.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 9.89%. Company’s average yearly earnings per share was noted 11.99% at the time writing. With a float of $93.80 million, this company’s outstanding shares have now reached $105.98 million.
Considering the fact that the conglomerate employs 500 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 98.43%, operating margin of 16.17%, and the pretax margin is 19.86%.
Corcept Therapeutics Inc (CORT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Corcept Therapeutics Inc is 11.55%, while institutional ownership is 78.70%. The most recent insider transaction that took place on Jul 01 ’25, was worth 7,350. In this transaction Chief Development Officer of this company sold 100 shares at a rate of $73.50, taking the stock ownership to the 5,487 shares. Before that another transaction happened on Jul 01 ’25, when Company’s insider sold 100 for $73.50, making the entire transaction worth $7,350. This insider now owns 10,066 shares in total.
Corcept Therapeutics Inc (CORT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 11.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 69.48% during the next five years compared to 9.89% growth over the previous five years of trading.
Corcept Therapeutics Inc (NASDAQ: CORT) Trading Performance Indicators
Check out the current performance indicators for Corcept Therapeutics Inc (CORT). In the past quarter, the stock posted a quick ratio of 2.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.45. Likewise, its price to free cash flow for the trailing twelve months is 40.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.15, a number that is poised to hit 0.19 in the next quarter and is forecasted to reach 2.66 in one year’s time.
Technical Analysis of Corcept Therapeutics Inc (CORT)
Compared to the last year’s volume of 1.45 million, its volume of 1.24 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.31%.
During the past 100 days, Corcept Therapeutics Inc’s (CORT) raw stochastic average was set at 23.27%, which indicates a significant increase from 9.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.17% in the past 14 days, which was lower than the 132.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $72.62, while its 200-day Moving Average is $61.05. Nevertheless, the first resistance level for the watch stands at $70.57 in the near term. At $73.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $75.63. If the price goes on to break the first support level at $65.51, it is likely to go to the next support level at $63.47. Now, if the price goes above the second support level, the third support stands at $60.45.
Corcept Therapeutics Inc (NASDAQ: CORT) Key Stats
There are currently 106,045K shares outstanding in the company with a market cap of 7.16 billion. Presently, the company’s annual sales total 675,040 K according to its annual income of 141,210 K. Last quarter, the company’s sales amounted to 157,210 K and its income totaled 20,550 K.
